Celltrion has kicked off plans for Phase III trials for its CT-P41 proposed biosimilar rival to Prolia (denosumab) after filing an investigational new drug application with the US Food and Drug Administration. The company has outlined plans for a Phase III study covering 416 patients across five countries.
With a goal of completing the Phase III trial in the first half of 2024, Celltrion expects to be ready to launch its denosumab biosimilar when
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?